Medical/Pharmaceuticals
CanSinoBIO Rebrands to Reflect Commitment to Life Sciences Research
TIANJIN, China, April 25, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO" of "the Company") (SSE: , HKEX: 06185) today announced its new brand identity, which is intended to represent the Company's continuous dedication to life sciences research and its commitment to protecting the glo...
2022-04-25 08:00
2239
Media Pooling Strategy to Increase Testing Throughput Added to Vela Diagnostics' ViroKey SARS-CoV-2 RT-PCR Test v2.0
FAIRFIELD, N.J., April 22, 2022 /PRNewswire/ -- Vela Diagnostics has announced that its ViroKey® SARS-CoV-2 RT-PCR Test v2.0 now has the additional capability to be used for pooling, using a three-in-one media pooling strategy. This FDA EUA authorized indication is authorized for use in laborator...
2022-04-22 20:00
1813
Novo Nordisk Indonesia takes a holistic approach to achieve zero environmental impact
JAKARTA, Indonesia, April 22, 2022 /PRNewswire/ -- In an attempt to achieve the company's ultimate goal to have zero environmental impact, Novo Nordisk Indonesia has initiated various activities, including switching the company's delivery method from air freight to sea freight and launching an in...
2022-04-22 17:39
3163
CStone Announces Results From Phase 3 AGILE Data of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia Published in the New England Journal of Medicine
* Results from the trial present a significant advancement for patients dealing with previously untreated IDH1-mutated AML * Global Phase 3 trial of TIBSOVO (ivosidenib tablets) met its primary endpoint of event-free survival and all key secondary endpoints, complete remission rate, overall s...
2022-04-22 08:02
3054
Lynk Pharmaceuticals Announces Clinical Approval in China for Its Class I New Drug LNK01004
HANGZHOU, China, April 22, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that its Class I innovative drug LNK01004, has been approved by National Medical Products Administration (NMPA) for c...
2022-04-22 08:00
2712
Telix Further Strengthens European Distribution Network for Illuccix
MELBOURNE, Australia and LIÈGE, Belgium, April 22, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces agreements with Sociedade Avanço, Unipessoal, LDA (Avanço) and THP Medical Products Vertriebs GmbH (THP) for the distribution of Telix's prostate ca...
2022-04-22 07:10
2753
Terran Biosciences announces licensing deal with Sanofi for two late-stage CNS pipeline assets
* Terran to advance the development of two of Sanofi's Phase 3 CNS therapeutics * Transaction includes worldwide exclusive rights for development and commercialization in all fields of use NEW YORK, April 21, 2022 /PRNewswire/ -- Terran Biosciences, Inc. ("Terran"), a biotech platform company...
2022-04-21 22:39
3021
Medical AI Startup Lunit gets Preliminary Approval to go Public on KOSDAQ
* Lunit gets greenlight to accelerate listing on the KOSDAQ market * First Korean healthcare company to receive "AA-AA" ratings in technology assessment SEOUL, South Korea, April 21, 2022 /PRNewswire/ -- Lunit, a leading medical AI provider, announced today a preliminary approval from the Kore...
2022-04-21 22:12
1608
Transcenta Successfully Passed the Audit of EU Qualified Person for the Manufacturing of TST001
SUZHOU, China, April 21, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that HJB (Hangzhou) ...
2022-04-21 19:20
2345
Wallaby Acquires German Neurovascular Leader Phenox to Accelerate Global Expansion
LAGUNA HILLS, Calif. and SHANGHAI and BOCHUM, Germany, April 21, 2022 /PRNewswire/ -- Wallaby Medical ("Wallaby" or the "Company"), a global innovative medical technology company focused on developing and commercializing neurovascular interventional products for treating stroke, today announced t...
2022-04-21 17:00
1056
Nippon Express Obtains IATA CEIV Pharma Certification for Temperature-controlled Facility at Kansai International Airport
TOKYO, April, 21, 2022 /PRNewswire/ -- Nippon Express Co., Ltd. (hereinafter "Nippon Express"), a group company of Nippon Express Holdings, Inc., has obtained IATA CEIV Pharma (*) pharmaceutical transport quality certification, effectiveApril 5, for its temperature-controlled facility "NX-PHARMA ...
2022-04-21 14:00
1626
Initial Results from Novavax' COVID-19-Influenza Vaccine Trial are First to Show Feasibility of Combination Vaccine
* Phase 1/2 clinical trial of COVID-19-Influenza combination vaccine candidate indicates vaccine is well-tolerated and immunogenic * Data from this combination trial will inform planned Phase 2 dose confirmation trial, scheduled to begin by the end of 2022 * Immune response confirmed in st...
2022-04-21 02:36
2613
REPROCELL Signs Agreement to Prospectively Collect Samples for IFF's Microbiome Study
BELTSVILLE, Md., April 20, 2022 /PRNewswire/ -- REPROCELL and IFF have entered into a clinical services agreement where in, REPROCELL will provide various types of samples for the study titled"Isolation and Characterization of Multiple Microbial Species from Diverse Healthy Adults (IsoMic)". The ...
2022-04-20 21:00
1851
JW Therapeutics Announces IND Approval for the Clinical Trial of Carteyva® in Pediatric and Young Adult Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
SHANGHAI, April 20, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced the Investigational New Drug (IND) clearance from the National Medical Products ...
2022-04-20 18:30
2396
Mentice's CEO Göran Malmberg to present the company's interim report at a webcast conference call on April 27 at 10:00 CEST
STOCKHOLM, April 20, 2022 /PRNewswire/ -- Mentice AB (STO: MNTC) announces that the company will present its interim report via webcast conference call with the opportunity for interested parties to ask questions to CEO Göran Malmberg and CFO Gunilla Andersson. To register for the presentation o...
2022-04-20 18:28
1538
Samsung Biologics completes full acquisition of Samsung Bioepis
* Samsung Biologics has now fully acquired Samsung Bioepis, as a wholly owned subsidiary * First payment completed funded through paid-in capital * Accelerated growth expected in biosimilars and future novel therapeutics R&D INCHEON,South Korea, April 20, 2022 /PRNewswire/ -- Samsung Biologi...
2022-04-20 14:45
1689
SNIPR BIOME Initiates First-in-Human Clinical Trial with SNIPR001
COPENHAGEN, Denmark, April 20, 2022 /PRNewswire/ -- SNIPR BIOME ApS, a leading CRISPR and microbiome gene therapy biotechnology company, today announced dosing of the first human subjects in its phase 1 clinical trial with SNIPR001, an orally administered CRISPR-based therapeutic. The purpose of...
2022-04-20 14:04
1612
FDA granted CMG901 Fast Track Designation for unresectable or metastatic gastric and gastroesophageal junction cancer which have relapsed and/or are refractory to approved therapies
CHENGDU, China, April 19, 2022 /PRNewswire/ -- Keymed Biosciences (2162.HK) announced that the U.S. Food and Drug Administration (FDA) granted CMG901 Fast Track Designation as monotherapy for the treatment of unresectable or metastatic gastric and gastroesophageal junction cancer which have relap...
2022-04-20 10:27
1299
ImmVira enters clinical development in combination therapy of MVR-T3011 IT and MEK inhibitor in the U.S.
SHENZHEN, China, April 19, 2022 /PRNewswire/ -- ImmVira announced that, company has reached a cooperation agreement with Roche to establish clinical research partnership recently, to conduct clinicalstudies in the U.S. on the combination therapy of ImmVira's MVR-T3011 IT and Roche's MEK inhibitor...
2022-04-20 08:00
1507
Treadwell Therapeutics Announces the Appointment of J.D. Mowery, as Chief Operating Officer
NEW YORK and HONG KONG, April 20, 2022 /PRNewswire/ -- Treadwell Therapeutics (" Treadwell"), a clinical-stage biotechnology company developing novel, cross-modality medicines for unmet needs in cancer, announced today the appointment of J.D. Mowery as Chief Operating Officer (COO). Reporting into...
2022-04-20 04:30
1768
Week's Top Stories
Most Reposted
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
[Picked up by 294 media titles]
2024-04-22 16:00
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
[Picked up by 291 media titles]
2024-04-22 06:00
Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
[Picked up by 275 media titles]
2024-04-23 15:43
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
[Picked up by 273 media titles]
2024-04-24 17:09
Introducing Wacom Movink: The first OLED pen display, and the thinnest and lightest Wacom pen display ever
[Picked up by 268 media titles]
2024-04-24 13:00
Most Read
Automation Anywhere Appoints Tim McDonough as Chief Marketing Officer to Drive Global Awareness and Growth for the Leader in AI-Powered Automation
2024-04-24 03:57
6229
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
2024-04-22 16:00
4457
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
2024-04-22 06:00
4051
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
2024-04-24 17:09
2944
Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
2024-04-23 15:43
2892